UBS Group set a $160.00 price target on Icon (NASDAQ:ICLR) in a research report sent to investors on Friday, TipRanks reports. The firm currently has a hold rating on the medical research company’s stock.
Several other brokerages have also recently weighed in on ICLR. ValuEngine cut Icon from a buy rating to a hold rating in a research note on Wednesday, September 11th. KeyCorp boosted their price objective on Icon from $157.00 to $165.00 and gave the stock an overweight rating in a research note on Thursday, August 8th. Zacks Investment Research raised Icon from a sell rating to a hold rating in a research note on Wednesday, October 23rd. Mizuho boosted their price objective on Icon from $160.00 to $170.00 and gave the stock a buy rating in a research note on Thursday, July 25th. Finally, BidaskClub cut Icon from a buy rating to a hold rating in a research note on Monday, September 30th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $163.25.
Shares of NASDAQ ICLR opened at $149.57 on Friday. The business’s 50 day moving average is $147.26 and its two-hundred day moving average is $147.11. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.07 and a quick ratio of 2.07. Icon has a 1-year low of $118.10 and a 1-year high of $165.13. The stock has a market capitalization of $7.89 billion, a P/E ratio of 23.78, a PEG ratio of 2.01 and a beta of 0.67.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.74 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.74. Icon had a return on equity of 25.30% and a net margin of 13.16%. The company had revenue of $710.40 million for the quarter, compared to analysts’ expectations of $709.75 million. During the same period in the previous year, the firm posted $1.54 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, equities research analysts anticipate that Icon will post 6.88 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. bought a new position in shares of Icon during the second quarter valued at approximately $47,000. UBS Asset Management Americas Inc. grew its stake in shares of Icon by 30.9% during the second quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock valued at $50,000 after buying an additional 77 shares during the last quarter. FTB Advisors Inc. grew its stake in shares of Icon by 27.6% during the third quarter. FTB Advisors Inc. now owns 361 shares of the medical research company’s stock valued at $52,000 after buying an additional 78 shares during the last quarter. CWM LLC grew its stake in shares of Icon by 65.0% during the third quarter. CWM LLC now owns 386 shares of the medical research company’s stock valued at $57,000 after buying an additional 152 shares during the last quarter. Finally, Coastal Capital Group Inc. bought a new position in shares of Icon during the second quarter valued at approximately $78,000. 83.53% of the stock is currently owned by hedge funds and other institutional investors.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: What is a price target?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.